CDT Equity (NASDAQ:CDT – Get Free Report) issued its earnings results on Monday. The company reported ($288.89) earnings per share for the quarter, FiscalAI reports.
CDT Equity Price Performance
NASDAQ:CDT opened at $0.36 on Wednesday. The firm has a 50-day moving average of $33.93 and a two-hundred day moving average of $22,760.10. CDT Equity has a 1-year low of $0.34 and a 1-year high of $291,250.00.
Analyst Ratings Changes
A number of equities analysts have weighed in on CDT shares. Weiss Ratings restated a “sell (e+)” rating on shares of CDT Equity in a report on Monday, September 21st. Wall Street Zen raised shares of CDT Equity from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the stock currently has a consensus rating of “Sell”.
About CDT Equity
CDT Equity (NASDAQ: CDT) is associated with the former Conduit Pharmaceuticals, a biotechnology company focused on developing drug candidates for diseases with unmet medical needs. Conduit’s historical pipeline included compounds licensed from AstraZeneca, with research directed toward areas including inflammation and autoimmune disease. The company’s approach was to advance existing drug candidates rather than discover medicines entirely from scratch. Conduit had operations and a corporate presence in the United Kingdom and the United States.
See Also
- Five stocks we like better than CDT Equity
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
Receive News & Ratings for CDT Equity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CDT Equity and related companies with MarketBeat.com's FREE daily email newsletter.
